Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
G01N-033/53
G01N-033/567
C12N-005/00
C12N-015/00
C12P-021/08
C07K-016/00
C07K-016/22
G01N-033/74
A61K-039/00
출원번호
US-0111507
(2012-04-11)
등록번호
US-9150644
(2015-10-06)
국제출원번호
PCT/US2012/033128
(2012-04-11)
§371/§102 date
20131011
(20131011)
국제공개번호
WO2012/142164
(2012-10-18)
발명자
/ 주소
Dimitrov, Dimiter S.
Zhu, Zhongyu
Zhao, Qi
출원인 / 주소
The United States of America, as represented by the Secretary, Department of Health and Human Services
대리인 / 주소
Klarquist Sparkman, LLP
인용정보
피인용 횟수 :
1인용 특허 :
65
초록▼
Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. N
Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.
대표청구항▼
1. An isolated human monoclonal antibody, or antigen binding fragment thereof, wherein the monoclonal antibody or antigen binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence set forth as
1. An isolated human monoclonal antibody, or antigen binding fragment thereof, wherein the monoclonal antibody or antigen binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence set forth as amino acids 26-33 of SEQ ID NO: 7, amino acids 51-58 of SEQ ID NO: 7, and amino acids 97-109 of SEQ ID NO: 7, wherein residue 56 is G and residue 109 is N; andwherein the light chain variable region comprises the amino acid sequence set forth as amino acids 27-32 of SEQ ID NO: 8, amino acids 50-52 of SEQ ID NO: 8 and amino acids 89-97 of SEQ ID NO: 8, wherein the human monoclonal antibody or antigen binding fragment specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 200 pM or less and specifically binds IGF-I with an equilibrium dissociation constant (Kd) of 200 pM or less. 2. The isolated human monoclonal antibody or antigen binding fragment of claim 1, wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 7, wherein residue 7 is L; residue 20 is V; residue 23 is K; residue 37 is V; residue 56 is G; residue 61 is A; residue 63 is Q; residue 74 is K; residue 76 is T; residue 77 is S; residue 79 is A; residue 85 is S; residue 87 is G; residue 109 is N; residue 111 is G; and residue 115 is L. 3. The isolated human monoclonal antibody of claim 1, wherein the antibody is an IgG or IgM. 4. The isolated human monoclonal antibody of claim 3, wherein the antibody is an IgM or an IgG4. 5. The antigen binding fragment of claim 1, wherein the antigen binding fragment is a Fab′ fragment, a F(ab)′2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv). 6. An isolated bispecific antibody comprising a first monoclonal antibody, or antigen binding fragment thereof, and a second monoclonal antibody, or antigen binding fragment thereof, wherein the first monoclonal antibody comprises the human monoclonal antibody or antigen binding fragment of claim 1, and the second monoclonal antibody or antigen binding fragment comprises a heavy chain variable region comprising amino acids 26-33 of SEQ ID NO: 23, amino acids 51-58 of SEQ ID NO: 23 and amino acids 97-109 of SEQ ID NO: 23, and a light chain variable region comprising amino acids 27-32 of SEQ ID NO: 24, amino acids 50-52 of SEQ ID NO: 24 and amino acids 89-98 of SEQ ID NO: 24, wherein the first monoclonal antibody or antigen binding fragment thereof specifically binds IGF-I and IGF-II, and wherein the second monoclonal antibody or antigen binding fragment thereof specifically binds IGF-II. 7. The isolated human monoclonal antibody or antigen binding fragment of claim 1, wherein the monoclonal antibody or antigen binding fragment is labeled. 8. The isolated human monoclonal antibody or antigen binding fragment of claim 7, wherein the label is a fluorescence, enzymatic, or radioactive label. 9. The isolated human monoclonal antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment binds IGF-I with an equilibrium constant (Kd) of 200 pM or less and binds IGF-II with an equilibrium constant (Kd) of 60 pM or less. 10. A composition comprising the human monoclonal antibody or antigen binding fragment of claim 1, and a pharmaceutically acceptable carrier. 11. A method of detecting insulin-like growth factor (IGF)-I and/or IGF-II in a biological sample from a subject, comprising contacting the biological sample from the subject with the composition of claim 10; anddetecting binding of the human monoclonal antibody or antigen binding fragment to the biological sample,wherein an increase in the binding of the human monoclonal antibody or antigen binding fragment to the biological sample as compared to a control indicates that IGF-I and/or IGF-II is present in the sample. 12. The method of claim 11, wherein the human monoclonal antibody or antigen binding fragment is directly labeled. 13. The method of claim 11 wherein the biological sample is assayed by competition immunoassay. 14. The method of claim 11 wherein the sample is tissue from a biopsy, autopsy, or pathology specimen. 15. The method of claim 11, wherein the sample is a blood, urine, biopsy, serum, sputum, plasma, cerebral spinal fluid sample. 16. A method of inhibiting phosphorylation of the insulin-like growth factor-I receptor, comprising contacting a cell that expresses IGF-I receptor on its cell surface with an effective amount of the composition of claim 10, thereby inhibiting the phosphorylation of the insulin-like growth factor receptor. 17. The method of claim 16, wherein the cell is in vitro. 18. The method of claim 16, wherein the cell is in vivo. 19. The method of claim 16, wherein the cell is a cancer cell. 20. A method of treating a subject with breast cancer, comprising administering to the subject a therapeutically effective amount of a composition comprising the isolated monoclonal antibody or antigen binding fragment of claim 1 to reduce tumor burden, tumor metastasis, or both, thereby treating the breast cancer in the subject. 21. The method of claim 20, wherein administering the therapeutically effective amount of the composition reduces breast cancer metastasis. 22. The method of claim 20, wherein administering the therapeutically effective amount of the composition inhibits the phosphorylation of the IGF-I receptor. 23. The isolated human monoclonal antibody of claim 1, wherein the monoclonal human antibody inhibits the motility of breast cancer cells in vitro. 24. The isolated human monoclonal antibody of claim 1, wherein the antibody inhibits phosphorylation of the insulin-like growth factor receptor. 25. An isolated bispecific antibody comprising a first scFv that binds IGF-I and IGF-II and a second scFv that binds IGF-II, wherein: the first scFV comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7, wherein residue 7 is L; residue 20 is V; residue 23 is K; residue 37 is V; residue 56 is G; residue 61 is A; residue 63 is Q; residue 74 is K; residue 76 is T; residue 77 is S; residue 79 is A; residue 85 is S; residue 87 is G; residue 109 is N; residue 111 is G; and residue 115 is L, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8, wherein residue 4 is M; residue 22 is V; residue 33 is V; residue 53 is S; residue 58 is V; residue 72 is A; and residue 108 is Q; andthe second scFv comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 24. 26. The bispecific antibody of claim 25, wherein the first scFv and second scFv are linked using linkers of G4S triplicates. 27. The bispecific antibody of claim 25, wherein the first scFv is fused to the N-terminus of the light chain constant region of an IgG1 and the second scFV is fused to the N-terminus of the heavy chain constant region of the IgG1, and wherein the first scFv and second scFv are fused to the IgG1 light chain and heavy chain constant regions using linkers of G4S.
Harpold Michael M. (El Cajon CA) Brust Paul (San Diego CA), Assay methods and compositions for detecting and evaluating the intracellular transduction of an extracellular signal.
Harpold Michael M. (San Diego CA) Brust Paul (San Diego CA), Assay methods and compositions useful for measuring the transduction of an intracellular signal.
Kay Robert M. (San Francisco CA) Berns Anton (Spaarndam NLX) Krimpenfort Paul (Heemstede NLX) Pieper Frank (Utrecht NLX) Strijker Rein (Oegstgeest NLX), Homologous recombination in mammalian cells.
Dunn Barbara (Los Altos CA) Choi Theodore K. (Berkeley CA), Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
Buttram Scott (Downingtown PA) Dean Richard T. (Downingtown PA) Lister-James John (Glenmoore PA) Pak Koon Yan (Norristown PA), One vial method for labeling antibodies with Technetium-99m.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Clark Steven C. (Winchester MA) Ciarletta Agnes B. (Tewksbury MA) Yang Yu-Chung (Arlington MA), Primate hematopoietic growth factors IL-3 and pharmaceutical compositions.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Rostoker Michael D. (Boulder Creek CA) Stelliga D. Tony (Pleasanton CA) Paolino Dave (Andover MA) Engelse Willem A. H. (Townsend MA), Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (C.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Deboer Herman A.,NLX ; Strijker Rein,NLX ; Heyneker Herbert L. ; Platenburg Gerard,NLX ; Lee Sang He,NLX ; Pieper Frank,NLX ; Krimpenfort Paul J. A.,NLX, Transgenic bovine.
Jakobovits,Aya; Kucherlapati,Raju; Klapholz,Susan; Mendez,Michael J; Green,Larry, Transgenic mammals having human Ig loci including plural Vand Vregions and antibodies produced therefrom.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.